The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

The Trump administration is planning an experiment to cover weight-loss drugs under Medicare and Medicaid, the Washington ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

The Washington Post editorial board argued a federal judge's ruling against congressional Medicaid restrictions on abortion ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

The Trump administration is preparing a five-year pilot program that could allow Medicare and Medicaid to cover expensive GLP ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

Shares of Eli Lilly And Co. (LLY) and Novo Nordisk (NVO) jumped on Friday following reports that the Trump administration is ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...